Provided by Tiger Fintech (Singapore) Pte. Ltd.

Apellis Pharmaceuticals Inc.

17.69
-0.0700-0.39%
Post-market: 17.860.1700+0.96%18:15 EDT
Volume:2.13M
Turnover:37.65M
Market Cap:2.22B
PE:-9.85
High:18.09
Open:17.85
Low:17.46
Close:17.76
Loading ...

Sector Update: Health Care Stocks Softer Friday Afternoon

MT Newswires Live
·
10 May

Apellis Pharmaceuticals Cut to Outperform From Strong Buy by Raymond James

Dow Jones
·
10 May

Apellis Pharmaceuticals' Funding Gaps, Weak Syfovre Sales Cloud Outlook, BofA Says

MT Newswires Live
·
09 May

Apellis Pharmaceuticals Inc : Bofa Global Research Cuts to Neutral From Buy; Cuts Price Objective to $23 From $41

THOMSON REUTERS
·
09 May

Apellis Pharmaceuticals Inc : Raymond James Cuts to Outperform From Strong Buy; Cuts Target Price to $52 From $75

THOMSON REUTERS
·
09 May

Apellis Pharmaceuticals Cut to Neutral From Buy by B of A Securities

Dow Jones
·
09 May

BofA Securities Downgrades Apellis Pharmaceuticals to Neutral, Price Target is $23

MT Newswires Live
·
09 May

Apellis price target lowered to $20 from $28 at Scotiabank

TIPRANKS
·
08 May

RBC Cuts Price Target on Apellis Pharmaceuticals to $18 From $21, Keeps Sector Perform Rating

MT Newswires Live
·
08 May

U.S. RESEARCH ROUNDUP-Axalta Coating, Gulfport Energy, Rockwell Automation

Reuters
·
08 May

Apellis Pharmaceuticals Inc : RBC Cuts Target Price to $18 From $21

THOMSON REUTERS
·
08 May

Apellis Pharmaceuticals Is Maintained at Buy by Needham

Dow Jones
·
08 May

Apellis Pharmaceuticals Shares Down 8.3% After Co Posts Bigger Q1 Loss

THOMSON REUTERS
·
07 May

Apellis Pharmaceuticals Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
07 May

Apellis Pharmaceuticals Q1 Loss Widens, Revenue Decreases

MT Newswires Live
·
07 May

Earnings Flash (APLS) Apellis Pharmaceuticals Posts Q1 Net Loss $0.74 a Share, vs. FactSet Est of $0.36 Loss

MT Newswires Live
·
07 May

Stock Track | Apellis Pharmaceuticals Plunges 5.23% Pre-market Following Q1 2025 Earnings Report

Stock Track
·
07 May

Stock Track | Apellis Pharmaceuticals Plunges 5.23% Pre-market on Disappointing Q1 2025 Results

Stock Track
·
07 May

Apellis Pharmaceuticals Q1 EPS $(0.74) May Not Be Comparable To $(0.35) Estimate, Sales $166.80M Miss $196.49M Estimate

Benzinga
·
07 May

BRIEF-Apellis Pharmaceuticals Q1 Basic EPS USD -0.74

Reuters
·
07 May